This report was first published by Endpoints News. To see the original version, click here
Merck is looking to further solidify its oncology pipeline via a $6.7 billion cash acquisition of Terns Pharmaceuticals and its investigational treatment for chronic myeloid leukemia.
The Wednesday morning M&A move gives the New Jersey drug giant access to TERN-701, a small molecule that Terns anticipates will enter the market before 2031 and could set it up for competition with Novartis’ blockbuster treatment Scemblix.
您已阅读10%（512字），剩余90%（4748字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。